IXJ:AU:AU-iShares Global Healthcare ETF (AUD)

ETF | Others |

Last Closing

USD 140.88

Change

+0.18 (+0.13)%

Market Cap

USD 1.46B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

-0.11 (-0.11%)

USD 16.05B
VGS:AU Vanguard MSCI International Sh..

-0.47 (-0.37%)

USD 8.59B
IVV:AU iShares Core S&P 500 AUD

-0.21 (-0.38%)

USD 8.26B
QUAL:AU VanEck Vectors MSCI World ex A..

-0.22 (-0.41%)

USD 6.31B
IOZ:AU Ishares Core S&P/Asx 200

-0.07 (-0.21%)

USD 6.10B
STW:AU SPDR® S&P/ASX 200 Fund

-0.10 (-0.14%)

USD 5.68B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

-0.68 (-1.68%)

USD 4.86B
NDQ:AU Betashares Nasdaq 100

-0.45 (-1.05%)

USD 4.83B
A200:AU BetaShares Australia 200

-0.21 (-0.15%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

-2.27 (-0.56%)

USD 4.70B

ETFs Containing IXJ:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.45% 70% C- 70% C-
Dividend Return 0.57% 4% F 3% F
Total Return 12.02% 61% D- 67% D+
Trailing 12 Months  
Capital Gain 10.43% 36% F 61% D-
Dividend Return 0.56% 5% F 4% F
Total Return 11.00% 29% F 59% D-
Trailing 5 Years  
Capital Gain 58.65% 89% A- 78% C+
Dividend Return 4.22% 8% B- 9% A-
Total Return 62.87% 84% B 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.30% N/A N/A 61% D-
Dividend Return 8.98% N/A N/A 58% F
Total Return 0.68% N/A N/A 13% F
Risk Return Profile  
Volatility (Standard Deviation) 7.21% N/A N/A 94% A
Risk Adjusted Return 124.43% N/A N/A 99% N/A
Market Capitalization 1.46B 87% B+ 87% B+

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike